Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis

Abstract

<b><i>Background:</i></b> The dosing of aminoglycosides (AGs) in patients with kidney disease is challenging due to their markedly prolonged half-life, which renders pulse dosing schedules unsuitable. We performed a review of the literature that describes the pharmacokinetics of, and dosing recommendations for, AG for patients with abnormal renal functions and various renal replacement therapy modalities, focusing on patients treated with intermittent hemodialysis (iHD). <b><i>Summary:</i></b> During one iHD session, dialysis removes a remarkable amount of the drug regardless of the dialyzer type. In patients with severely reduced kidney functions, the distribution phase is prolonged, which needs to be taken into account when drawing samples shortly after drug administration or following an iHD session. <b><i>Key Messages:</i></b> The doses recommended for the pulse dosing of patients without kidney disease leads to unacceptably high overall systemic exposure for patients with severely reduced kidney functions even with dosing intervals extended up to 48 h. Therefore, lower doses accompanied by extended dosing intervals must be applied for this patient group. The clinical evidence and current recommendations support the dosing of AG following, rather than before, HD sessions. In patients with end-stage kidney disease, the samples for TDM of AGs should not be drawn earlier than 2 h after end of the infusion and 4 h after the end of iHD session to allow full (re)distribution of the drug.

Elimination and penetration of amikacin into urine in patients with decreased glomerular filtration rate

“…Administration of lower doses over extended intervals would lead to similar urinary concentration and potentially lower risk of systemic toxicity. This is in line with various current guidelines that do not recommend once-daily dosing in patients with markedly reduced GFR [ 12 ].…”

The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping

“…Foscarnet, which is used to treat ganciclovir-resistant CMV infections, is efficacious but also associated with nephrotoxicity, with rates as high as 60% during therapy due primarily to acute tubulointerstitial nephritis, which can lead to renal dysfunction [ 52 ]. Furthermore, side effects of drugs given for complications of CMV, for example, aminoglycosides given for neutropenic fever due to poor graft function, can lead to severely reduced kidney function [ 53 ]. Poor graft function is a life-threatening complication following allo-HSCT.…”